This paper, written by members of the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) subcommittees for the angiotensin receptors, confirms the existing nomenclature for these receptors and reviews our current understanding of their structure, pharmacology and functions, and their likely physiological roles in health and disease. More information on these receptor families can be found in the Concise Guide to PHARMACOLOGY Angiotensins are a group of hormonal peptides and include angiotensin II and angiotensin 1-7 produced by the renin angiotensin system. The biology, pharmacology and biochemistry of the receptors for angiotensins were extensively reviewed recently. In the review, the receptor nomenclature committee was not emphatic on designating MAS1 as the angiotensin 1-7 receptor on the basis of lack of classical G protein signalling and desensitization in response to angiotensin 1-7, as well as a lack of consensus on confirmatory ligand pharmacological analyses. A review of recent publications (2013-2016) on the rapidly progressing research on angiotensin 1-7 revealed that MAS1 and two additional receptors can function as 'angiotensin 1-7 receptors', and this deserves further consideration. In this review we have summarized the information on angiotensin 1-7 receptors and their crosstalk with classical angiotensin II receptors in the context of the functions of the renin angiotensin system. It was concluded that the receptors for angiotensin II and angiotensin 1-7 make up a sophisticated cross-regulated signalling network that modulates the endogenous protective and pathogenic facets of the renin angiotensin system.
Introduction
The classical renin angiotensin system (RAS) regulates (i) the production of the hormone angiotensin II (AngII) from angiotensinogen, which involves renin and angiotensin converting enzyme 1 (ACE1), and (ii) the initiation of the homeostatic physiological response to AngII, predominantly through the AngII type 1 (AT 1 ) receptor (Karnik et al., 2015; Singh and Karnik, 2016) . Both the production and cellular actions of this octapeptide hormone are critical body functions, because deletion of genes for either angiotensinogen or the AT 1 receptors increases mortality in mice (Tsuchida et al., 1998; Doan et al., 2001) . In humans, clinical application of RAS blockers does not necessarily lower AngII, instead, an increase in tissue and circulating AngII levels is observed, suggesting that their therapeutic effects are probably due to metabolized AngII products. The presumptive therapeutic messenger of RAS is the heptapeptide metabolite, Ang(1-7). Ang(1-7) has been characterized as an antagonist of the pathophysiological effects of AngII (Ferrario et al., 1991; Iyer et al., 1998) . Subsequently, the mono-carboxypeptidase ACE2 (Lemos et al., 2002; Ren et al., 2002) was shown to be the major enzyme producing Ang(1-7) in vivo from proteolysis of AngII. These discoveries led to the bifurcation of RAS with the addition of a new ACE2 arm (Figure 1 ), which produces Ang(1-7). ACE2 has been shown to cleave multiple peptide substrates and play a role in amino acid uptake in the gut. Moreover, ACE2-knockout mice have been extensively used to elucidate the in vivo functions of . Recent studies have demonstrated that increasing ACE2 in tissues up-regulates levels of Ang(1-7), which are directly associated with a reduction in the progression of neuronal, renal and cardiovascular diseases including pulmonary arterial hypertension (PAH). Thus, the ACE2/Ang(1-7) axis may have evolved to counterbalance the pathophysiological effects of overactivation of the classical ACE1/AngII axis in vivo (Bradford et al., 2010; Ahmad et al., 2011; de Kloet et al., 2013; Jiang et al., 2014a,b) . Characterization of receptor components of the ACE2/Ang(1-7) axis, however, is unfinished and currently in progress.
The finding that the GPCR, MAS (also called MAS1) mediates some of the actions of Ang(1-7) was a breakthrough in unravelling the body's response mechanism to Ang(1-7) . Initially MAS1 was discovered as a growth promoting GPCR (Young et al., 1986; Janssen et al., 1988; Dean and Boynton, 1990; van't Veer et al., 1993) and was erroneously proposed as a receptor for AngII and AngIII; AT 2 receptor ACE2 B 1 receptor p70S6K but this assignment was later withdrawn (Jackson et al., 1988; Jackson and Hanley, 1989; McGillis et al., 1989; Sasamura et al., 1992) . This time around, the investigations showed that Ang(1-7) elicited arachidonic acid release in MAS1-transfected cells. Mas1 gene deleted mice are normal, but the binding of Ang(1-7) in their kidney slices is abolished, Ang(1-7)-induced relaxation response in the aorta is lost and the antidiuretic action of Ang(1-7) after an acute water load is abolished . Mas1 gene-null mouse tissues and organs respond poorly to Ang(1-7) (Walther et al., 1998; Fraga-Silva et al., 2008; Santos et al., 2008; Mario et al., 2012) . However, independent laboratories have reported a lack of MAS1 receptor signalling in response to Ang(1-7) and a lack of evidence for direct Ang(1-7) binding to the MAS1 receptor (Bikkavilli et al., 2006; Shemesh et al., 2008; Zhang et al., 2011; Tirupula et al., 2014a) . There is evidence in the literature for additional receptors mediating the effects of Ang(1-7) (Figure 2 ). For example, the AT 2 receptor was shown to bind Ang(1-7) (De Souza et al., 2004; Walters et al., 2005) and Ang(1-7) signals through AT 2 receptors in some studies (Jones et al., 2011; Sipahi et al., 2011; Ohshima et al., 2014) , although this is not replicated in all settings (Lautner et al., 2013; Mendonca et al., 2014; Tetzner et al., 2016) . De-orphanization efforts on the MAS1-related GPCR (MRGPR) family have uncovered potential new receptors for consideration in the ACE2/Ang(1-7) pathway (Gembardt et al., 2008; Solinski et al., 2014) . Functional studies indicate that the MRGPRD (MrgD) receptor mediates acute and persistent responses to Ang(1-7) and its metabolite alamandine in target tissues akin to those produced by MAS1 receptors (Habiyakare et al., 2014; Wilson et al., 2015; Tetzner et al., 2016) .
Tables of Links
The confusing pharmacology and transduction modalities for MAS1, the awareness of ligand-promiscuity among MRGPRs and evidence of MRGPRs responding to other angiotensin metabolites (Bader et al., 2014) have delayed a conclusive designation of MAS1 receptors and other candidate MRGPR receptors as the Ang(1-7) receptor by the IUPHAR/BPS subcommittee (Karnik et al., 2014; 2015; Singh and Karnik, 2016) . In addition, the classification in Pharmacological Reviews (Davenport et al., 2013; Solinski et al., 2014) and the IUPHAR/BPS guide to pharmacology Database (http://www.guidetopharmacology.org/) have included MAS1 and MRGPRD (MrgD) in the list of 'orphan' GPCRs for which pairing with the endogenous ligand(s) is inconclusive. The aim of this review is to provide the present status of the field of candidate Ang(1-7) receptors, with focus on recent important findings and particularly the challenges for future research.
The progress in coupling Ang(1-7) functions with MAS1 receptors MAS1 was originally identified as the oncogenic GPCR in skin cancer cell lines and is currently catalogued under a group of ∼40 orphan MRGPRs by the HUGO gene nomenclature committee and the IUPHAR/BP database (Monnot et al., 1991; Dong et al., 2001; Gembardt et al., 2008; Tirupula et al., 2014b) . Tissue distribution of the MAS1 receptor is ubiquitous; it is abundantly expressed in the brain and testes whereas its expression is low in the heart, kidneys, lungs, vasculature, adipose tissue and skeletal muscle. The MAS1 receptor may regulate many vital body functions and its
Figure 2
A current view of the three receptors proposed to signal in response to Ang(1-7). MrgD receptor is also known as MRGPRD receptor.
dysfunction may lead to various pathologies. There is emerging evidence suggesting an important role for Ang(1-7)'s interaction with MAS1 receptors in the function of the brain as well as that of multiple organs including the kidney, heart, vasculature, skeletal muscle, retina and the liver. MAS1 is a constitutively active GPCR; hence, changes in MAS1 expression levels could affect signalling pathways and thus may function without requiring a ligand. However, the MAS1 receptor is reported to bind various endogenous ligands including Ang(1-7), alamandine and neuropeptide FF (NPFF) and dimerize with other GPCRs (Figure 2) . However, the physiological significance of these diverse mechanisms remains unclear. In this section, we summarize findings published in past 3 years ending August 2016 on the physiology and pathology involving MAS1 receptors linked to the ACE2/Ang(1-7) pathway (Bader, 2013; Solinski et al., 2014; Karnik et al., 2015) . In reviewing recent functional studies on MAS1 receptors, we have tried to limit the inclusion of observations supported by a single publication. We have strived, in vain, to find unequivocal pharmacological evidence for a formal adoption of the MAS1 receptor as the Ang(1-7) receptor.
The promise of novel therapeutic approaches targeting the ACE2/Ang(1-7) axis appears to be the major impetus for the continuing interest in MAS1 functions in the brain for treatment of ischaemic stroke and cerebrovascular diseases (see Figure 1 ). Enhancing systemic ACE2/Ang(1-7) axis is thought to attenuate the development of hypertension and the pathological progress of atherosclerosis and prevent thrombogenic events, which may contribute to a reduced risk of ischaemic stroke, a reduction in cerebral infarct size and amelioration of neurological deficits; these are thought to be mediated through its antioxidative and anti-inflammatory effects. Excellent reviews that highlight these topics are available (Bader, 2013; Jiang et al., 2013; Montezano et al., 2015; Silva and Pinheiro, 2015; Bennion et al., 2015a,b; Colafella et al., 2016; Machado-Silva et al., 2016; Simoes and Teixeira, 2016) The neuroprotective effects mediated by enhancing ACE2 or Ang(1-7) in ischaemic and haemorrhagic stroke have spurred interest in neuroprotective mechanisms of MAS1 in the clinical setting. The expression of ACE2 and MAS1 receptors are up-regulated after acute cerebral ischaemic stroke in rats . Also a deficiency in MAS1 receptors has been found to exacerbate cerebral and systemic inflammation in mice (Oliveira-Lima et al., 2015) . In stroke-prone spontaneously hypertensive rats, a haemorrhagic stroke model, centrally administered Ang(1-7) increased the survival of the rats, suggesting that the MAS1 receptor is a potential therapeutic target in haemorrhagic stroke Regenhardt et al., 2013a,b) . When Ang(1-7) is injected into regions of the hypothalamus that control cardiovascular function, the BP is reduced. However, Ang(1-7) injection into the rostral ventrolateral medulla increases BP. It has been suggested that Ang(1-7) has a critical role in the control of baroreflex sensitivity and hypothalamic noradrenergic neurotransmission during the development of hypertension (Gironacci et al., 2014; Bennion et al., 2015a,b) . Cerebral damage is enhanced in mice overexpressing human renin and angiotensinogen and experimental ischaemic stroke induced in brain slices from these mice in vitro by oxygen and glucose deprivation caused tissue swelling, which was associated with the production of ROS and cell death. When these mice were treated with Ang(1-7) the damaging effects were reduced and treatment with the MAS1 antagonist A-779 eliminated this protective effect of Ang(1-7) (Regenhardt et al., 2013c; Zheng et al., 2014a) . Infusion of Ang(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a MAS1/eNOS-dependent pathway which is reversed by the specific MAS1 antagonist A-779 (Jiang et al., 2014a,b; Zheng et al., 2014b) . The mortality rate due to rupture of intracranial aneurysms in mice is reduced by intracranial injection of Ang(1-7) (Pena . IN diabetic rats Ang(1-7) treatment up-regulates the expressions of GFAP and GDNF promoting neuron survival in the hippocampus, and this effect was blocked by treatment with A-779 . In chronic neurogenic hypertension microglial activation and the production of proinflammatory cytokines, IL-1β and TNFα, and the antiinflammatory cytokine IL-10 can be abolished by Ang (1-7) . In contrast the MAS1 antagonist A-779 enhances inflammation and microglial activation suggesting that 'neurogenic' hypertension may be targeted by MAS1 .
The overexpression of ACE2 in the brain was found to activate central MAS1-induced spontaneous postsynaptic inhibitory currents, indicative of presynaptic GABA release onto pyramidal neurons, which reduced anxiety-like behaviour in mice; the MAS1 antagonist A-779 eliminated this effect. Furthermore, centrally administering A-779 abolished the anxiolytic phenotype in ACE2-null mice (Oscar et al., 2014; Fontes et al., 2015; Wang et al., 2016) . Indeed, activation of the brain Ang(1-7)/MAS1 axis in hypertensive transgenic (mRen2)27 rats lowered BP and attenuated cardiac remodelling by improving the autonomic balance (Kangussu et al., 2015) . In female rats, central Ang(1-7) protects against aldosterone/NaCl-induced hypertension, by decreasing heart rate and renal sympathetic nerve activity (Xue et al., 2013) . In Sprague-Dawley rats, Ang(1-7) injected into the nucleus tractus solitarii (NTS) decreases BP, heart rate and renal sympathetic nerve activity through the generation of NO (Wu et al., 2015) .
Ang(1-7) mediated MAS1 activation has been evaluated as an antinociceptive intervention. Treatment with Ang(1-7) significantly attenuated bone pain suggesting it could be used in the relief of excruciating pain in advanced stage cancer patients (Forte et al., 2016) . Intraplantar peripheral hyperalgesia induced by PGE 2 was reversed by a low-dose of Ang(1-7) Nemoto et al., 2014; Castor et al., 2015) .
In animal studies and in small human subgroups, treatments selectively targeting different components of the RAS are changing the perspectives for the prevention of the pathophysiology of heart failure and coronary atherothrombosis. In renal arteries from diabetic patients, ex vivo Ang(1-7) treatment reduced oxidative stress (Zhang et al., 2015b) . The central ACE2/Ang(1-7) axis is a key player in the regulation of sympathetic outflow in chronic heart failure (Zucker et al., 2014) , the risk of adverse cardiovascular events in response to acute emotional stress (Martins Lima et al., 2013; Xing et al., 2014) , and also cellular hypertrophy and myofibroblast transformation (Alzayadneh and Chappell, 2014) . Vascular sympathetic modulation mediated through BJP S S Karnik et al.
the ACE2/Ang(1-) axis is well-documented (Rabello Casali et al., 2016) . These studies indicate that Ang(1-7) is involved in producing NO through MAS1, which contributes to the variations in heart rate in the autonomic modulation of arterial pressure and cardiovascular regulation (Abwainy et al., 2015; da Silva et al., 2015; Zhang et al., 2015c ). An increased expression of the ACE2/Ang(1-7) axis is observed in hyperthyroidism-induced cardiac hypertrophy (Diniz et al., 2015) and in a pressure overloaded rat model (Liang et al., 2015a,b) . In an acute atrial tachycardia canine model, Ang(1-7)/MAS1/PI3K/Akt/NO/atrial natriuretic peptide prevented acute electrical remodelling . Cardioprotection by Ang(1-7) against AngII-induced cardiac remodelling through inhibition of cardiomyocyte autophagy is also reported (Lin et al., 2015) . Pharmacological blockade or genetic deletion of MAS1 attenuates physiological cardiac hypertrophy that can occur during pregnancy (Carmos- . Treatment with Ang(1-7) reduces inflammation in carotid atherosclerotic plaques (Fraga-Silva et al., 2014) . Long-term administration of Ang(1-7) prevents inflammation and pathological remodelling of the heart and lung in a mouse model of type 2 diabetes Papinska et al., 2016) . Ang(1-7) reverses hyperglycaemia and its consequences in an animal model of type 2 diabetes (Santos et al., 2013) . Ang(1-7) regulates insulin secretion through a MAS-dependent cAMP signalling pathway (Sahr et al., 2016) .
Analysis of muscular expression of various components of the RAS in patients with achalasia has shown the existence of local RAS in human oesophageal and skeletal muscle. In the epithelium of patients with healthy and acid reflux-exposed human oesophageal mucosae, the expression of RAS components, particularly ACE2, ACE, AT 1 and AT 2 receptors and MAS1, was reported to vary (Bjorkman et al., 2012) . In patients with achalasia, a shift in receptor physiology from AT 1 receptor to MAS1 receptor is reported (Casselbrant et al., 2014) . The healing of pre-existing gastric ulcers is associated with an up-regulation of Ang(1-7), MAS1, NO, prostaglandins and pro-inflammatory cytokines and a decreased expression of AT 1 receptors has been observed during the local vascular and metabolic effects associated with gastric ulcer healing (Pawlik et al., 2016) . The gastric mucosal protection mechanism involves a similar scenario (Brzozowski, 2014; Lu et al., 2014) . After the induction of experimental colitis, the colonic expression of ACE2, Ang1-7 and MAS1 was enhanced and daily Ang(1-7) treatment significantly reduced colitis, whereas administration of A-779 significantly increased colitis (Khajah et al., 2016) .
In skeletal muscle, RAS activation induces insulin resistance and impairs glucose uptake, which is counterbalanced by actions of the ACE2/ANG(1-7)/MAS1 axis (Henriksen and Prasannarong, 2012) . Ang(1-7) affects muscle microvasculature and enhances insulin's metabolic action via the MAS1 receptor (Fu et al., 2014) . Chronic oral administration of Ang(1-7) has been shown to improve skeletal muscle insulin sensitivity, and autonomic and locomotor phenotypes in muscular dystrophy (Echeverria-Rodriguez et al., 2013; Gomes-Santos et al., 2014; Sabharwal et al., 2014; Morales et al., 2014a,b) . Endotoxin-induced skeletal muscle wasting can be prevented by Ang(1-7) through a p38 MAPKdependent mechanism. Ang(1-7) prevents the decrease in the diameter of myofibres and myotubes, and decrease in muscle strength induced by LPS. These effects were reversed by the MAS1 receptor antagonist A-779 Morales et al., 2015) . Ang(1-7) reduces myonuclear apoptosis during recovery from AngII-induced skeletal muscle atrophy in mice , and attenuates signalling involving TGF-β both in vitro and in vivo (Morales et al., 2014a,b) . The oral administration of Ang(1-7) in a mouse model of Duchenne muscular dystrophy (DMD) normalized skeletal muscle architecture, decreased local fibrosis and improved muscle functions. These effects are mediated through inhibition of TGF-β Smad signalling (Acuna et al., 2013) . Ang(1-7) could contribute to weight gain in this model (Schuchard et al., 2015) . Recent reviews on kidney diseases discuss new research elucidating the role of ACE1 and ACE2 in haemodialysis patients, which may aid the development of targeted therapies that slow the progression of chronic kidney and cardiovascular diseases (Carey, 2015; Malik and Raizada, 2015; Oparil and Schmieder, 2015; Te Riet et al., 2015) . The antiinflammatory effects of Ang(1-7) could ameliorate high fat diet-induced renal injury. The administration of Ang (1-7) significantly improved the inflammatory status, down regulated LDLr, SREBP2 and SCAP, and then, decreased the deposits of lipid in the kidney and improved renal injury (Olivon et al., 2015; Zheng et al., 2015b ). An up-regulation in the expression of ACE2/AT 2 receptors and MAS1 receptors in diabetic mice is associated with the renoprotective effects of candesartan in db/db mice suggesting that the ACE-2/ Ang(1-7) axis can be a therapeutic target for diabetes-induced hypertension and renal damage (Callera et al., 2016; Padda et al., 2016) . The endothelial progenitors may be dysfunctional in diabetic mice. In patients with diabetes, Ang(1-7) overexpression by lentiviral delivery restored both the in vitro vaso-reparative functions and the in vivo homing efficiency of the peripheral blood CD34+ cells to areas of ischaemia compared with those of nondiabetic controls. In a cohort of patients who had higher expression of ACE2/MAS1 receptors than diabetic patients, the development of CD34+ cell dysfunction was reduced. Thus, activating the ACE2/Ang(1-7)/MAS1 receptor axis could overcome endothelial dysfunction and enhance the reparative function of endothelial progenitors (Jarajapu et al., 2012; Singh et al., 2015) .
The expression of MAS1 receptors and other components of the renin-angiotensin system were shown in the human eye, suggesting that MAS1 receptors may have a role in physiological and pathological processes in the eye and in the retina (Vaajanen et al., 2015) . The expression and cellular localization of MAS1 receptors in the adult and developing mouse retina is also documented (Prasad et al., 2014 ) the activation of intrinsic ACE2 has been shown to have antiglaucomatous effects (Foureaux et al., 2013) . Several independent reports suggest that deletion of ACE2 leads to vascular diseases (Thomas et al., 2010; Thatcher et al., 2011; Sahara et al., 2013; Rabelo et al., 2016) . Furthermore, the MAS axis may be an interesting therapeutic target for multiple sclerosis and atherosclerosis (Hammer et al., 2016) and hypothermia (Souza et al., 2014) . Activation of MAS could be an important target for the chronic hepatic and metabolic alterations during atherosclerosis ). An impairment of the Ang(1-7)/Mas receptor pathway may lead to a worsening of the pathophysiological changes in asthma (Magalhaes et al., 2016) .
Experimental model studies
Central Ang(1-7) treatment of hypertensive (mRen2)27 transgenic rats attenuates the anxiety and depression-like behaviour in these animals (Almeida- Wang et al., 2016) . In a chronic constriction injury rat model, intrathecal administration of Ang(1-7) relieves, whereas A-779 aggravates injury-induced neuropathic pain . The MAS1-null mice may serve as an animal model to study post-traumatic stress disorder. Ang(1-7)/ MAS1 axis deficits may accelerate memory extinction in the MAS1-null mice (Lazaroni et al., 2015) . In a mouse model of Alzheimer's disease, i.c.v. infusion of Ang(1-7) ameliorated the cognitive impairments and memory dysfunction (Uekawa et al., 2016) . In models of Alzheimer's and Parkinson's diseases, Ang(1-7) activity correlates with tau hyperphosphorylation (Wright et al., 2013; Jiang et al., 2015) . The Ang(1-7)/MAS1 axis affects the proliferation of the population of doublecortin positive cells within the dentate gyrus and the piriform cortex. A deficiency of MAS1 in the null mice increases the number of DCX-positive young neurons, suggesting that blockade of MAS1 might be beneficial in stimulating neurogenesis in adults (Freund et al., 2013) .
Ang(1-7) counteracted the inflammation involved in vascular remodelling and haemorrhagic stroke in cerebral micro vessels by affecting the NFкB-mediated expression of TNF-α, MCP-1 and IL-8 (Bihl et al., 2015) . The cardiomyopathy and diastolic dysfunction in diabetic (db/db) mice is ameliorated by Ang(1-7) (Mori et al., 2014) . Long-term administration of Ang(1-7) prevents heart and lung dysfunction in db/db mice (Papinska et al., 2016) . In Ren-2 transgenic rats exposed to chronic hypoxia, intrapulmonary activation of the ACE2/Ang(1-7)/MAS1 axis attenuates pulmonary hypertension (Hampl et al., 2014) . In an acute lung injury model, Ang(1-7) attenuates lung fibrosis . The ACE2/Ang(1-7)/MAS1 axis inhibits the MAPK/NF-κB pathway to protect against lung fibrosis (Meng et al., 2013) . In a rat model of neonatal hyperoxia-induced lung injury, MAS1 and AT 2 receptor agonists attenuate cardiopulmonary disease (Wagenaar et al., 2013) . In a model of chronic allergic lung inflammation, Ang(1-7) attenuates lung inflammation, airway remodelling and hyperresponsiveness (Magalhaes et al., 2015; Murugan et al., 2015) . Deletion of the MAS1 gene significantly increased intimal proliferation, increasing the aortic intima : media ratio, which promotes atherogenesis (Alsaadon et al., 2015) .
The role of RAS has been examined in models of liver disease model, so as to evaluate it as a target for the treatment and prevention of liver dysfunction (Moreira de Macedo et al., 2014). The ACE2/Ang(1-7)/MAS1 axis activates Akt signalling to ameliorate hepatic steatosis. Deletion of the ACE2 gene aggravates liver steatosis and insulin resistance, increases the expression of hepatic lipogenic genes and decreases the expression of fatty acid oxidation genes in mice (Cao et al., 2016) . In ACE2 knockout mice, Ang(1-7) alleviates insulin resistance and oxidative stress (Cao et al., 2014 ).
In a model of acute reflux oesophagitis, Ang(1-7) exerts a protective effect on the oesophagus through the involvement of NO, sensory nerve hypoxia-inducible factor-1α and proinflammatory cytokines IL-1β and TNF-α (Pawlik et al., 2015) . In an acetic acid-induced gastric ulcer model, Ang(1-7) accelerates the healing of pre-existing gastric ulcers by increasing the macro-and microcirculation, which increases gastric tissue oxygenation. Blockade of MAS1 receptors by A-779 abolishes this healing effect of Ang(1-7) mediated by PGs and NO, and increases the expression of the antioxidizing enzyme SOD 2 and cytokines IL-1β and TNF-α (Pawlik et al., 2016) . Ang(1-7) attenuates disuse atrophy in skeletal muscle. The classical RAS is activated in the immobilized hind limb of C57BL6 mice and Ang(1-7) treatment increased anti-atrophic signalling by IGF-1/IGFR-1/ Akt/p70S6K and FoxO3. These effects of Ang(1-7) were not observed in MAS1 knockout mice (Morales et al., 2016) . Ang1-7 restored muscle strength in dystrophic muscles through the inhibition of TGF-β signalling in a mouse model of Duchenne muscular dystrophy (Morales et al., 2016) .
Kidney injury caused by unilateral ureteral obstruction (UUO) in a Sprague-Dawley rat model of nephropathy was attenuated by Ang(1-7). Renal tubulointerstitial apoptosis, expression of profibrotic proteins, pro-apoptotic proteins and (TGF)-β1/Smad signalling, were reduced by Ang(1-7) treatment. Treatment with A-779 and MAS1 receptor siRNA enhanced Ang II-induced apoptosis and fibrosis . Ang(1-7) normalizes renal ACE2 and MAS1 receptor expression in Type 1 diabetic Akita mice (Shi et al., 2014) . Ang(1-7) attenuates the progression of streptozotocininduced renal injury, and this is accompanied by a decreased expression of collagen IV, TGF-β1, VEGF, NOX4, p47phox, PKCα and PKCβ1, and the phosphorylation of Smad3 . Ang(1-7) modulates renal vascular resistance through inhibition of p38 MAPK in apolipoprotein E-deficient mice (Potthoff et al., 2013) .
Confusing evidence
The results of the studies summarized above support the identification of MAS1 as the receptor mediating the in vivo effects of Ang(1-7). This designation is primarily based on the loss of Ang(1-7)-mediated functional responses in MAS1-null animal models and the antagonism of MAS1-regulated physiology by the specific antagonist, A-779 (Santos et al., 1994; . In some studies, surrogate MAS1-specific agonists AVE0991 (Wiemer et al., 2002) and CGEN-856S (Shemesh et al., 2008) and another antagonist and D-Pro7-Ang(1-7) have been used, but not regularly. However, a direct assessment of the functional effects of Ang(1-7) in different vascular tissues in humans, rats and various disease models has raised some concerns regarding the pairing of Ang(1-7) with the MAS1 receptor. In a recent study, the therapeutic potential of Ang(1-7) for the treatment of PAH was found to be limited as opposed to the huge benefits reported in other models of cardiovascular diseases. The effectiveness of Ang(1-7) and a stable, cyclic analogue, cAng(1-7), was found to be limited in a rat experimental monocrotaline (MCT) model of PAH. Treatment reduced right ventricular BJP S S Karnik et al.
systolic pressure, but this reduction was <50% and not significant (Breitling et al., 2015) .
In human mammary artery (HMA) samples obtained from patients undergoing coronary revascularization surgery, MAS1 expression was confirmed in endothelium. Also, acute Ang(1-7) treatment attenuates the AngII-induced constriction of HMA explants. Unexpectedly, pre-incubation with the specific MAS1 antagonist A-779 did not abolish this effect of AngII. Furthermore, the Ang(1-7) effect observed in HMA was not altered by the AT 2 receptor antagonist PD123177, indicating a pharmacologically distinct receptor in HMA (Mendonca et al., 2014) .
In the cirrhotic rat liver Ang(1-7) induces a vasodilator response and the activation of endothelial NOS (eNOS) by phosphorylation. This effect of Ang (1-7) was not blocked by MAS1-selective antagonist A-779 or by blockade of AT 1 , AT 2 and bradykinin B 2 receptors. Unexpectedly, the observed Ang(1-7) effects were not reproduced by MAS1-selective agonist AVE0991. However, the D-Pro 7 -Ang(1-7) analogue antagonized all the functional effects of Ang (1-7). These findings suggest that the Ang(1-7)-induced beneficial effects in cirrhosis are mediated by receptors that are pharmacologically distinct from the MAS1 receptor (Herath et al., 2012) . In the splanchnic vessels of patients and rat cirrhosis model similar observations were reported (Grace et al., 2013) . Pharmacological evidence for the existence of a distinct Ang(1-7) receptor was obtained in the aorta from Sprague-Dawley rats, also the Ang(1-7)-induced vasodilator effect was not blocked by A-779, but was specifically abolished by D-Pro 7 -Ang(1-7) . Altogether, these findings indicate the existence of an Ang(1-7) receptor that is not sensitive to A-779.
MAS1-related GPCR MRGPRD (MrgD) coupling with Ang(1-7)/alamandine
Characterization of the MAS1-related GPCR (MRGPR) subfamily may help better understand the confusion as regards Ang (1-7) pairing with the MAS1 receptor. More than 40 members of this receptor family have been identified in multiple species. They are expressed in sensory neurons, and thought to be involved in the perception of itch, pain and pathological pain (Solinski et al., 2014; Tiwari et al., 2016) . Most MRGPR are orphan receptors. However, de-orphanization efforts have led to new receptors pairing with the ACE2/Ang(1-7) pathway (Figure 2 ). For instance, while screening an assortment of MRGPRs for arachidonic acid release in response to angiotensin metabolites, Gembardt et al. discovered that in addition to the MAS1 receptor, Ang IV [Ang(3-8)] stimulated AA release in MRGPRD (MrgD) and MRGPRX1 (Mrg1) transfected cells. AngIII activated MAS1 and MRGPRX2 receptors. This initial study lead to further characterization of the MRGPR family of GPCRs as potential targets of Ang(1-7) and related peptides (Gembardt et al., 2008) . The MRGPRD receptor may mediate NO dependent vasodilator effects of a relatively new heptapeptide, alamandine, which structurally differs from Ang(1-7) with an Ala replacing the N-terminal Asp and is thought to be produced in vivo from Ang A by the action of ACE2 (Lautner et al., 2013) . Ang A has Ala 1 instead of Asp 1 in AngII. It was first identified in human plasma. Alamandine was identified in rats, mice and humans, where it is thought to produce the same effects as Ang(1-7), but by interacting with the MRGPRD receptor (Mendoza-Torres et al., 2015) . The alamandine-induced effects have been shown to be abolished by D-Pro-Ang(1-7), and the AT 2 receptor antagonist PD123319. The binding of alamandine to the MRGPRD receptor is blocked by the MRGPRD agonist β-alanine, D-Pro 7 -Ang(1-7) and PD123319, but not by the MAS1 antagonist A-779. Direct radioligand binding and rigorous pharmacological analysis data were provided to support the claim that MRGPRD is the alamandine receptor (Habiyakare et al., 2014; Wilson et al., 2015) . MRGPRD or MRGPRD-like receptors may explain the findings that in certain circumstances Ang(1-7) effects are not blocked by A-779 (Etelvino et al., 2014; Solinski et al., 2014; Villela et al., 2014a,b) .
A recent study independently claimed that MRGPRD is the receptor for Ang(1-7) in addition to alamandine and the AT 2 receptor antagonist, PD123319 (Lautner et al., 2013; Tetzner et al., 2016) . Using the cAMP readout assay (instead of arachdonic acid release assay), the authors showed functional activation of MAS1 receptors by Ang(1-7) in transfected HEK293 cells, contradicting data from previous independent studies (Bikkavilli et al., 2006; Shemesh et al., 2008; Zhang et al., 2011; Tirupula et al., 2014a) . Furthermore, the authors presented data showing that MRGPRD functions as a receptor for Ang(1-7) . In their analysis, Ang(1-7) failed to increase cAMP levels in primary mesangial cells obtained from MAS1 and MRGPRD double knockout mice. The haemodynamic response to Ang(1-7) was also impaired in MRGPRD-null mice. In this study, the Ang-(1-7) stimulated arachidonic acid release was modest compared to the cAMP response in MRGPRD-transfected heterologous cells. Furthermore, the authors demonstrated polypharmacology of PD123319, which blocks the signalling by MAS1 and MRGPRD receptors as well as from the AT 2 receptor.
AT 2 receptor coupling with Ang(1-7)
Reports from multiple laboratories have highlighted an Ang(1-7)/AT 2 receptor axis as a new protective arm of the RAS (Gaspari et al., 2012) . AT 2 receptor-dependent protective effects of Ang(1-7) against aneurysmal subarachnoid haemorrhage development in mice is reported. The protective effect of Ang(1-7) was not observed in AT 2 receptor knockout mice. Furthermore, the protective effects of Ang (1-7) were blocked by the AT 2 receptor antagonist PD123319, but not by the MAS1 receptor antagonist A-779. These findings indicate that protective effect of Ang(1-7) against aneurysmal rupture is mediated by AT 2 receptors (Shimada et al., 2015) . AT 2 receptor expression is up-regulated in many disease states suggesting a role for this receptor in disease (Gaspari et al., 2012) . In the apolipoprotein E À/À mouse model of atherosclerosis, Ang(1-7) can act via the AT 2 receptors to exert vasoprotective and atheroprotective effects and these effects of Ang(1-7) can be abolished by either the AT 2 receptor antagonist PD123319 or A-779 (Pernomian et al., 2015) . AT 2 receptor stimulation by Ang(1-7) has been shown to lower BP in adult normotensive rats (Walters et al., 2005) .
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Furthermore, the effects of Ang(1-7) on vascular remodelling and its ability to inhibit neointimal growth are attenuated in AT 2 receptor knockout mice compared with wild-type mice. Surprisingly, Ang(1-7)-dependent attenuation of neointimal formation after vessel injury in the MAS1-null mice requires an increased expression of AT 2 receptors (Ohshima et al., 2014) . In a mouse model of UUO, the administration of Ang(1-7) caused injury in obstructed kidneys compared with controls and increased macrophage infiltration. In mice with MAS1 gene deletion, the delivery of exogenous Ang(1-7) worsens kidney damage. Surprisingly, an infusion of Ang(1-7), but not A-779 further increased apoptosis and macrophage influx in obstructed kidneys from MAS1-null mice compared with untreated mice (Zimmerman et al., 2015) . Could these effects be due to an unknown receptor or are mediated by the AT 2 receptor? Taken together, these findings suggest that the AT 2 receptor is a an important mediator of effects attributed to the ACE2/Ang(1-7) axis.
Pharmacology
The suggestion that Ang (1-7) is the physiological agonist for the MAS1 receptor is based on the loss of physiological effects of Ang(1-7) and reduced [ 125 I]-Ang(1-7) binding to kidney sections in MAS1-null mice Pinheiro et al., 2004a,b) . Generally, specificity and a dissociation constant for the ligand or receptor density are not measured in these types of experiments. Despite impressive advances made through functional characterization supporting MAS1 receptors coupling to Ang(1-7), attempts at pharmacological analysis of MAS1 receptors in tissue membrane preparations have shown that [ 125/127 I]-Ang(1-7) binding is not specific.
Furthermore, in competitive displacement experiments, Ang(1-7) is less potent than other angiotensin metabolites, leading to the suggestion that either the radioligand binding sites in tissue membrane preparations are non-specific or the isotope modifies Ang(1-7) in such a way as to affect the highaffinity interaction (Conti, 2016) . Additional radioligand development could help resolve this problem. Concentration-response studies in MAS1 as well as MAS1-GFP transfected cells have been used to estimate an IC 50 for the Ang(1-7) antagonist, D-Ala7-Ang(1-7) and K d values of [ 125 I]-Ang(1-7) Gironacci et al., 2011) .
The binding specificity of fluorescently labelled Ang(1-7) has been studied in CHO cells (Pinheiro et al., 2004a,b; Savergnini et al., 2010; Jankowski et al., 2011 ), platelets (Fraga-Silva et al., 2008 and Leydig cells (Leal et al., 2009) . Also the MAS1 receptor mediated signalling has been found to be stimulated by several other peptides such as NPFF, alamandine, Ang III, Ang IV, angioprotectin, CGEN-857 and P61/P33 and CGEN-856. Some of the peptides have also been found to elicit a response through the MRGPRD receptor, but additional systematic studies are warranted (Dong et al., 2001; Bikkavilli et al., 2006; Canals et al., 2006; Gembardt et al., 2008; Shemesh et al., 2008; Savergnini et al., 2010; Jankowski et al., 2011; Zhang et al., 2012; Savergnini et al., 2013; Tirupula et al., 2014a; Lee et al., 2015) . In transfected HEK293 cells, the MAS1 receptor was found to activate G q/ 11 -PKC signalling without ligand stimulation (Canals et al., 2006) . Several ligands that modulate MAS1 receptor signalling by other G-proteins and receptor desensitization have been described. These include peptide ligands such as MBP7 (Bikkavilli et al., 2006) , NPFF, AngIII, AngIV and the small nonpeptide agonist AR234960 and inverse agonist AR244555 Tirupula et al., 2014a) . G protein mediated cAMP signalling by MAS1 and MRGPRD receptors in response to stimulation by peptides and non-peptide ligands have been recently reported (Tirupula et al., 2014a; Klein et al., 2015; Tetzner et al., 2016) . Ang(1-7) has been shown to increase arachidonic acid levels but, it does not modulate G q -PLC signalling in MAS1-expressing cells (Bikkavilli et al., 2006; Shemesh et al., 2008; Zhang et al., 2011; Tirupula et al., 2014a) leading to the concept of functional selectivity of ligands interacting with MAS1 receptors (Tirupula et al., 2014a) .
Signalling
Ang(1-7)-or AVE0991-activated MAS1 receptors have been demonstrated to couple to many downstream signalling pathways (see Figure 2) including activation of phospholipase A 2 , release of arachidonic acid, calcium-independent activation of NOS, activation of phosphatidylinositol 3-kinase/ Akt, MAP kinases, RhoA, and cAMP/PKA in human mesangial cells and MAS1 transfected CHO and COS cells Sampaio et al., 2007a,b; Gembardt et al., 2008; Zimpelmann and Burns, 2009; Liu et al., 2011; Lopez Verrilli et al., 2011; Verano-Braga et al., 2012; Savergnini et al., 2013; Than et al., 2013) . In early studies in MAS1 transfected cells, treatment with Ang(1-7) or AVE099 did not produce a G protein coupled calcium, IP3 and cAMP signalling response (Bikkavilli et al., 2006; Shemesh et al., 2008) . However, this observation was disputed by findings in the kidney, where Ang(1-7) treatment increased cAMP levels and activated PKA through Gα s activation by MAS1 receptors. These signals could be inhibited using A-779 (Magaldi et al., 2003; Liu et al., 2011) . The MAS1 receptor was also shown to constitutively couple to Gα i , Gα q and Gα 12/13 proteins (Zohn et al., 1998; Whitehead et al., 2001; Booden et al., 2002; Chen and Ikeda, 2004; Dias-Peixoto et al., 2008; Shemesh et al., 2008; Singh et al., 2010; Zhang et al., 2011; Gomes et al., 2012; Tirupula et al., 2014a) . Conventional G protein signalling by MAS1 receptors was reported upon stimulation with neuropeptide FF (Dong et al., 2001; Tirupula et al., 2014a) , MBP7 (Bikkavilli et al., 2006) , the angiotensin metabolites, AngIII and AngIV (Gembardt et al., 2008; Tirupula et al., 2014a) , novel nonpeptide ligands, AR234960, AR244555 and AR305352 Tirupula et al., 2014a) and CGEN-856/P61 (Shemesh et al., 2008; Savergnini et al., 2010) . Thus, this atypical G protein response may be due to the functional selectivity of the MAS1 receptor, which allows different ligands to activate different signalling pathways (Tirupula et al., 2014a) . Calcium-independent activation of NOS, and Gi/omediated cAMP signalling is reported for Ang(1-7) engaged with AT 2 and MRGPRD receptors. However, additional validation studies are required to elucidate the ligand selectivity of different modes of signalling in these receptors.
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receptors in transfected cells (Kostenis et al., 2005; Canals et al., 2006; Santos et al., 2007) . The physiological effects of Ang(1-7) treatment in mice may involve MAS1 receptors interacting with AT 1 and AT 2 receptors (Castro et al., 2005) . The MAS1 receptor was shown to function as a physiological antagonist of the AT 1 receptor by altering the response to AngII in the mice (Von Bohlen und Halbach et al., 2000; Kostenis et al., 2005; Rakusan et al., 2010) . Thus, the interaction of MAS1 receptors with AT 1 and AT 2 receptors may be a mechanism for the MAS1 receptor in RAS pathophysiology (Villela et al., 2014a) . In experimental disease models Ang(1-7)/MAS1 signalling suppress AngII-induced pathogenesis. For example, AngII-induced ROS overproduction and apoptosis in cerebral endothelial cells , phosphorylation of c-Src and MAPKs, leading to production of TGF-β1 and collagen in cardiac fibroblasts Tao et al., 2014; Zheng et al., 2015a) , muscle atrophy of gastrocnemius (Cisternas et al., 2014) , pancreatic cell damage , ICAM-1, VCAM-1, and MCP-1 expression in HUVECs (Liang et al., 2015a,b) is suppressed by Ang(1-7) activated MAS1 receptors.
Similarly, receptor heterodimer dependent crosstalk between the bradykinin B 2 receptor and MAS1 receptor was implicated in vasorelaxation responses. Microvessels in MAS1-deficient mice lacked the capacity to relax in response to both Ang(1-7) and bradykinin (Peiro et al., 2013) . Fluorescence resonance energy transfer analysis showed that the B 2 receptor and MAS receptor formed a constitutive heteromer, leading to potentiation of agonist binding to both receptors. B 2 receptor or MAS1 receptor antagonists promoted heteromer dissociation. Agonist stimulation promoted internalization of the heteromer into early endosomes. B 2 receptor-MAS1 receptor hetromers have been shown in human glomerular endothelial cells by proximity ligation assay (Cerrato et al., 2016) .
G protein independent signalling scaffold proteins have been shown to interact with the MAS receptor C-terminal tail in a tissue specific manner . This mechanism may explain the signalling events that were demonstrated to be not associated with the generation of G protein mediated second messengers. The MAS receptor has been shown to interact with postsynaptic density 95 (PSD95), a novel binding protein. MAS interacts with the PDZ1-2 domain of PSD95 through engaging the last four amino acids [ETVV (Glu-Thr-Val-Val)] of MAS-CT. This interaction with PSD95 enhanced the expression and proteolysis stability of MAS receptors in cells (Bian et al., 2013 ). An agonist driven 'MAS-signalosome' model has also been proposed as molecular mechanism of MAS receptor function. Identifying the hierarchy of interactions of 'signalosome' components with MAS receptors will be a necessary step in the future to fully understand the physiological and pathological functions of this enigmatic receptor .
Conclusion
Initially, the pairing of Ang(1-7) with the MAS1 receptor generated huge excitement, in part, due to the lack of a reasonable alternative target for Ang(1-7) at the time. However, now three Ang(1-7) receptor candidates have been proposed by independent groups, all of which meet some of the criteria used by IUPHAR in their de-orphanization efforts. Firstly, the findings that Ang(1-7) stimulates the MAS1, MRGPRD and AT 2 receptors with potencies consistent with physiological function have been independently established. Secondly, the distribution of ACE2 -the enzyme producing Ang(1-7) at physiologically significant concentrations -is anatomically co-localized with endogenous MAS1, MRGPRD and AT 2 receptors, which supports the local production and action of Ang(1-7) . Thirdly, genetic modification affecting each of these three receptors alters the physiological response to Ang(1-7) in experimental models. The Ang(1-7)/MAS1 receptor axis currently seems to be most studied beneficial counter-regulator of the effects of activation of the reninangiotensin system in several neurological and cardiovascular diseases. In comparison, the Ang(1-7)/MRGPRD and Ang(1-7)/AT 2 receptor pairing require extensive further evaluation. A recent paper has proposed an Ang(1-7)/AT 1 receptor biased signalling mechanism (Galandrin et al., 2016) , but this needs independent confirmation. Improving the validity of the pharmacological tests, including saturation, competitive radioligand binding and signalling assays, which may further support and strengthen the Ang(1-7) pairing with each of these GPCRs would be most helpful. The criteria that selective agonists should mimic and antagonists should selectively block the signals of the endogenous ligand through each of these GPCRs are not uniformly established for all putative ligands. The recent discovery of an AT 2 receptor-selective antagonist PD123319, which inhibits the action of Ang(1-7) mediated through MAS1 and MRGPRD receptors, is a case in point for the confusing state of molecular pharmacology of Ang(1-7) receptors. However, the existence of multiple receptors responding to Ang(1-7) may have evolved for tissue-specific sensitive effects. A specific Ang(1-7) receptor axis may mediate a particular effect, which depends on the concentration of one or other of the receptors in a tissue. Until the unique distinctions of each receptor pairing with Ang(1-7) emerges, the adoption of these receptors strictly as Ang(1-7) receptors by the nomenclature committee may well be provisional.
